These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 16416761)

  • 21. Pharmacoeconomics of long-acting risperidone: results and validity of cost-effectiveness models.
    Haycox A
    Pharmacoeconomics; 2005; 23 Suppl 1():3-16. PubMed ID: 16416758
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Sweden.
    Mehnert A; Nicholl D; Pudas H; Martin M; McGuire A
    J Med Econ; 2012; 15(5):844-61. PubMed ID: 22458756
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost effectiveness of paliperidone palmitate for the treatment of schizophrenia in Germany.
    Zeidler J; Mahlich J; Greiner W; Heres S
    Appl Health Econ Health Policy; 2013 Oct; 11(5):509-21. PubMed ID: 23975630
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France.
    Druais S; Doutriaux A; Cognet M; Godet A; Lançon C; Levy P; Samalin L; Guillon P
    Pharmacoeconomics; 2016 Apr; 34(4):363-91. PubMed ID: 26883132
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A decision model to compare health care costs of olanzapine and risperidone treatment for schizophrenia in Germany.
    Beard SM; Maciver F; Clouth J; Rüther E
    Eur J Health Econ; 2006 Sep; 7(3):165-72. PubMed ID: 16896764
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Olanzapine: an updated review of its use in the management of schizophrenia.
    Bhana N; Foster RH; Olney R; Plosker GL
    Drugs; 2001; 61(1):111-61. PubMed ID: 11217867
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost analysis of the treatment of schizophrenia in Thailand: a simulation model comparing olanzapine, risperidone, quetiapine, ziprasidone and haloperidol.
    Kongsakon R; Leelahanaj T; Price N; Birinyi-Strachan L; Davey P
    J Med Assoc Thai; 2005 Sep; 88(9):1267-77. PubMed ID: 16536115
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A cost-effectiveness clinical decision analysis model for schizophrenia.
    Palmer CS; Revicki DA; Genduso LA; Hamilton SH; Brown RE
    Am J Manag Care; 1998 Mar; 4(3):345-55. PubMed ID: 10178497
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost analysis of the treatment of schizophrenia in the UK. A simulation model comparing olanzapine, risperidone and haloperidol.
    Almond S; O'Donnell O
    Pharmacoeconomics; 2000 Apr; 17(4):383-9. PubMed ID: 10947493
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of long-acting risperidone injection versus alternative atypical antipsychotic agents in patients with schizophrenia in China.
    Yang L; Li M; Tao LB; Zhang M; Nicholl MD; Dong P
    Value Health; 2009; 12 Suppl 3():S66-9. PubMed ID: 20586985
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Economic evaluation of antipsychotic drugs for schizophrenia treatment within the Brazilian Healthcare System.
    Lindner LM; Marasciulo AC; Farias MR; Grohs GE
    Rev Saude Publica; 2009 Aug; 43 Suppl 1():62-9. PubMed ID: 19669066
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of antipsychotics for outpatients with chronic schizophrenia.
    Obradovic M; Mrhar A; Kos M
    Int J Clin Pract; 2007 Dec; 61(12):1979-88. PubMed ID: 17997804
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a medicaid population.
    Gibson PJ; Damler R; Jackson EA; Wilder T; Ramsey JL
    Value Health; 2004; 7(1):22-35. PubMed ID: 14720128
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Economic and clinical comparison of atypical depot antipsychotic drugs for treatment of chronic schizophrenia in the Czech Republic.
    Einarson TR; Zilbershtein R; Skoupá J; Veselá S; Garg M; Hemels ME
    J Med Econ; 2013 Sep; 16(9):1089-95. PubMed ID: 23808900
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Cost-effectiveness Analysis of Antipsychotics for Treatment of Schizophrenia in Uganda.
    Lubinga SJ; Mutamba BB; Nganizi A; Babigumira JB
    Appl Health Econ Health Policy; 2015 Oct; 13(5):493-506. PubMed ID: 25958192
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Olanzapine. A pharmacoeconomic review of its use in schizophrenia.
    Foster RH; Goa KL
    Pharmacoeconomics; 1999 Jun; 15(6):611-40. PubMed ID: 10538333
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-acting injectable risperidone for the treatment of schizophrenia: clinical perspectives.
    Möller HJ
    Drugs; 2007; 67(11):1541-66. PubMed ID: 17661527
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness analysis of atypical long-acting antipsychotics for treating chronic schizophrenia in Finland.
    Einarson TR; Pudas H; Zilbershtein R; Jensen R; Vicente C; Piwko C; Hemels ME
    J Med Econ; 2013 Sep; 16(9):1096-105. PubMed ID: 23844621
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-utility analysis of treatment with olanzapine compared with other antipsychotic treatments in patients with schizophrenia in the pan-European SOHO study.
    Knapp M; Windmeijer F; Brown J; Kontodimas S; Tzivelekis S; Haro JM; Ratcliffe M; Hong J; Novick D;
    Pharmacoeconomics; 2008; 26(4):341-58. PubMed ID: 18370568
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-Minimisation Analysis of Paliperidone Palmitate Long-Acting Treatment versus Risperidone Long-Acting Treatment for Schizophrenia in Spain.
    Quintero J; Oyagüez I; González B; Cuervo-Arango I; García I; Casado MA
    Clin Drug Investig; 2016 Jun; 36(6):479-90. PubMed ID: 27000061
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.